Spirair
Develops minimally invasive ENT medical devices for physicians treating nasal and sinus conditions
Highlights
- New on EvolcAdded 2026-11-13
About Spirair
Spirair develops medical devices for ear, nose and throat care. Its commercially available products include SeptAlign, a cartilage-preserving septoplasty treatment, and TurbAlign, a solution for middle turbinate medialization after sinus surgery.
The company partners with physicians to develop solutions intended to simplify procedures and preserve anatomy. It was founded in 2020 by two Stanford Biodesign Innovation Fellows.
Spirair is hiring an R&D Engineer (Medical Device) in South San Francisco, California.
Product: SeptAlign and TurbAlign medical devices for septoplasty and middle turbinate medialization.
Jobs at Spirair
More health & medtech companies
Spring Fertility
Fertility clinics offering IVF, IUI and egg freezing to patients in California, Oregon, New York and ColoradoNew on EvolcSpring Health
Mental health care platform offering therapy, coaching and related support through employers, health plans and self-pay to individualsNew on EvolcSpringleafsolutions
Outpatient mental health and substance use treatment for individuals, families and couples in Washington, DCNew on EvolcSprinter Health
Hybrid in-home and virtual preventive care for health plans and their membersSSI Diagnostica Group
Infectious disease diagnostics and life-science products for clinical laboratories, healthcare professionals, vaccine makersSt. Jude
Pediatric hospital and research institute advancing treatments for children with cancer and other life-threatening diseasesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- SquarespaceHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.